As one of the key areas of Beijing's "two districts" construction, the biomedical industry has achieved fruitful results in the past two years. Yesterday, at the press conference for the second anniversary of the construction of the "two districts" (the special session for the opening of the whole industrial chain of biomedicine), the relevant responsible comrades of Beijing Drug Administration, Beijing Administration of Traditional Chinese Medicine, Changping District and Daxing District respectively released the relevant achievements of the construction of the "two districts". According to the relevant person in charge of the Beijing Food and Drug Administration, since the implementation of the first implementation plan for the opening of the whole industrial chain, the Beijing Implementation Plan for the Opening of the Whole Industrial Chain of Biomedical Industry (hereinafter referred to as the "Plan") for the construction of the "two districts" in Beijing in February this year, 38 projects have been completed, with a completion rate of 76%, and 6 of the 13 projects that need the authorization and consent of the relevant national departments have been implemented; Thirty two of the 37 policies and measures related to the authority of the city have been completed. Qu Haopeng, deputy director and spokesman of Beijing Food and Drug Administration, introduced that the Plan is the first implementation plan for the opening of the whole industrial chain for the construction of the "two districts" in Beijing, which not only provides policy support for the leapfrog development of Beijing's biomedical industry, but also makes a useful exploration for the development of the national free trade pilot zone and the reform and opening up of the national biomedical industry. The Plan is problem oriented, putting forward 17 50 policy measures and suggestions, accelerating the gathering of innovation elements and facilitating the flow, building new mechanisms, exploring new practices, and helping the new opening up. So far, 38 of the 50 measures have been completed, with a completion rate of 76%. 13 items requiring authorization and consent from relevant national departments have been implemented; Thirty two of the 37 policies and measures related to the authority of the city have been completed. Beijing actively gives play to the capital's resource advantages, takes the lead in breaking through the existing approval and management methods nationwide, and opens the door to the industry. With the support of the General Administration of Customs, Beijing has adopted a new supervision model of one customs approval and multiple clinical trials for the entry quarantine of stem cells and other derived cells for clinical trials, which further simplifies the entry formalities of human derived cells and realizes intensive and efficient supervision. Under the support and guidance of the State Food and Drug Administration, Beijing Pharmaceutical and Medical Device Innovation Service Station has provided services to enterprises. In the first half of this year alone, 17 innovative drugs and medical devices were approved in Beijing, ranking first in the country. Qu Haopeng introduced that Beijing implemented the "white list" system for the import of R&D articles of biomedical enterprises, which fundamentally solved the bottleneck problem of the import of R&D articles. At the same time, focusing on the implementation effect of the policy, the formulation of the plan and the project reserve were promoted at the same time. The pilot plan was introduced on June 20, and the first batch of "white list" was released on June 28. On August 5, the "levobupivacaine suspension" and "polyethylene glycol 300 solution" of Beijing Zhaoyan New Drug Research Center were successfully cleared in the capital airport, and the research and development of a new drug variety has started. The "white list" has broken through a key blocking point in the R&D link and boosted the process of new drug innovation and research. Aiming at exploring a new mode of co construction and sharing of health care data, and further strengthening the standardization of clinical medical data and the open communication between hospitals, the Municipal Health Commission has formulated the Beijing Intelligent Medical Health Implementation Plan, which determines the overall goal of intelligent medical health, forms the overall architecture of Beijing intelligent medical health, and creates a community that includes services